BRAF and neoplasm: Importantly, these methylation-dependent subtypes stratify disease outcome; MSI tumours are clinically favourable, but respond poorly to 5-fluorouracil-based chemotherapy (Ribic et al, 2003; Carethers et al, 2004), whereas CIMP tumours have complex associations with patient outcome that may depend on MSI and/or BRAF V600E status (Kim et al, 2009; Ogino et al, 2009; Dahlin et al, 2010).